NeuBase Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Sep 30, 2022	FY2021 12 months to Sep 30, 2021	FY2020 12 months to Sep 30, 2020	FY2019 12 months to Sep 30, 2019	FY2018 12 months to Sep 30, 2018
OPERATING EXPENSES
General and administrative
Research and development
Depreciation and amortization
Loss on Impairment of Goodwill
Loss on Impairment of intangible asset
Gain on settlement of liabilities
Research and development expense- license acquired
Research and development, Vera acquisition
TOTAL OPERATING EXPENSES

LOSS FROM OPERATIONS
OTHER INCOME (EXPENSE)
Interest expense
Interest income
Change in fair value of warrant liabilities
Total other expenses
Loss on disposal of fixed asset
Equity in losses on equity method investment
Other income, net
Other (expense) income, net
Interest income (expense), net
Total other (expense) income, net

INCOME TAXES
NET LOSS
BASIC AND DILUTED LOSS PER SHARE (in dollars per share)
BASIC AND DILUTED
BASIC LOSS PER SHARE (in dollars per share)
DILUTED LOSS PER SHARE (in dollars per share)
WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC
DILUTED

Comments